INTRODUCTION
Nucleic-acid amplification tests (NAATs) for tuberculosis (TB) have been commercially available in the United States and Europe for almost two decades (1, 2) . During that time, evidence has accumulated showing that NAATs provide excellent diagnostic accuracy (3, 4) and additional value for diagnosing TB over clinical decision-making alone (5, 6) . This evidence has led U.S. Centers for Disease Control and Prevention (CDC) (7) (8) (9) and the British Thoracic Society (10) to recommend routine use of NAATs to guide initial management of patients with possible TB. Nevertheless, NAATs have not been widely adopted in the United States (11) or the United Kingdom (12) . Most public health laboratories do not perform TB NAATs routinely (12, 13) , because first-generation commercial assays are labor-intensive and have not proven cost-effective in low-burden countries (14) (15) (16) . Evidence of clinical impact is mixed, with some studies suggesting that NAATs rarely change management in these settings, especially when NAAT results are negative (17, 18) . Newer data, however, suggest that among the subset of individuals selected to undergo NAAT, these assays can influence a variety of management decisions, and be costsaving in some sub-populations of patients (19) .
The GeneXpert MTB/RIF® assay ("Xpert", Cepheid Diagnostics, Sunnyvale, California) is a novel, semi-automated NAAT with similar diagnostic accuracy to first-generation commercial NAATs (20, 21) .
Many clinical laboratories already use the Xpert platform for other diagnostic applications, and its minimal labor requirements make it simpler, faster, and potentially cheaper than previous NAATs. The European Union and World Health Organization have endorsed Xpert for TB evaluation (22) , and on July 25, 2013, U.S. Food and Drug Administration (FDA) authorized its use for TB evaluation in the U.S. (23) .
In spite of Xpert's attractive diagnostic and operational characteristics, the poor uptake of firstgeneration NAATs suggests that data on diagnostic accuracy alone could be insufficient to drive Hypothetical Impact of Xpert Davis et al 6 adoption and that evidence on clinical and public health decision-making and outcomes may be needed (24) (25) (26) . Therefore, we designed a prospective observational study to estimate the hypothetical impact of Xpert as a replacement for standard clinical and programmatic criteria used in risk stratification and triage of patents undergoing evaluation for active pulmonary TB, while awaiting results of mycobacterial culture and longitudinal clinical assessment (27) .
METHODS

Study design and population
The hypothetical trial comparing the impact of different diagnostic strategies represents a novel study design (27) , and may be useful when ethical concerns, regulatory barriers, or sample size limitations make a randomized trial infeasible (28, 29) . Hypothetical trials are observational studies which make paired measures of diagnostic accuracy for different evaluation strategies, and then project how the results of novel strategies might hypothetically affect management decisions and patient outcomes relative to the actual decisions and outcomes observed for the control strategy.
In this study, we screened consecutive adults undergoing evaluation for active pulmonary TB at the San Francisco Department of Public Health TB Clinic between May 2010 and June 2011 and asked clinicians to refer individuals in whom they believed a NAAT result could inform clinical or public health decisions, a priority group for testing according to CDC guidelines (9) . We suggested two key groups of patients for Xpert testing: those initiating empiric treatment for active TB (i.e., treatment prior to a confirmed mycobacterial culture result); and those coming from congregate settings (e.g., homeless shelters, behavioral treatment programs, dialysis centers), in whom an inability to rapidly assess TB transmission risk often interrupts the patient's residence or care in the congregate environment and prompts orders for housing and contact investigation. We excluded patients with incomplete positives defining TB and two or more negatives with no positives defining non-TB status), we calculated and compared the sensitivities, specificities, and positive and negative predictive values of Xpert and of key clinical and public health decisions. These included decisions to 1) initiate TB treatment; 2) conduct contact investigation; and 3) provide subsidized housing. For discordant results, we reviewed patient records, and reported final clinical diagnoses in accordance with American Thoracic Society TB diagnostic standards (34) . We used McNemar's test for paired proportions to assess the statistical significance of differences in sensitivity and specificity, and the large sample test for unpaired proportions to assess differences in predictive values.
Next, for the period prior to the availability of final culture results only, we measured the consequences of Xpert-guided and standard decisions on treatment, contact investigation, and subsidized housing for individuals and for the program in aggregate over the approximately one-year period of the study. Using measures of the time to report results for all diagnostic assays, we calculated differences between standard and Xpert strategies for the following outcomes among those with and without culture-confirmed TB: days of treatment; numbers of close contacts undergoing TB contact investigation; and days of subsidized housing (Online Supplement). We compared differences in medians using Wilcoxon's signed-rank test and differences in proportions using the chi-squared test.
For all analyses, we defined significance in reference to the probability of a two-tailed, type I error (p-value) less than 0.05. Because the sample size arose from convenience, we estimated the precision of outcomes using 95% confidence intervals (95%CI) (35) . We performed all statistical analyses using STATA version 11.0 (Stata Corporation, College Station, Texas). 
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RESULTS
Study enrollment
Of 538 consecutive patients undergoing evaluation for possible pulmonary TB during the 13-month study, 227 met eligibility criteria, including 132 patients coming from congregate settings and 95 patients receiving empiric treatment (Figure 1 Table S2 ).
Patient characteristics
Median age was 52 years (interquartile range (IQR) 39-60), and 54 (35%) were women ( Table 1) .
One-hundred seventeen (75%) were foreign-born, of whom 46 (39%) had immigrated to the U.S. within the previous five years. Twenty (13%) patients were homeless. Thirty-three (21%) reported a history of viral hepatitis, chronic liver disease, or regular ethanol use. Thirteen (8%) were HIV-infected. Although exact medication lists were not available for all patients, 64 (41%) reported taking one or more medications from drug classes commonly associated with TB drug interactions (i.e., antiretroviral therapy, oral contraceptives, immunosuppressive medications, or methadone). Fifteen (10%) were immunosuppressed. Among those tested with Xpert, the clinician-estimated probability of TB was low in 79 (51%) patients, moderate in 44 (28%), and high in 33 (21%). Twenty-two (14%) had positive sputum AFB-smear microscopy results, but only eleven (50%) of these had positive results on M. tuberculosis complex cultures. Two patients with negative microscopy results had positive culture results. In total, 13 (8.3%) patients had culture-confirmed TB, including 1/97 (1.0%) from congregate settings, and 12/59 (20%) receiving empiric treatment. The public health laboratory completed Xpert testing in a median of two days (IQR 1-3) , and tested 95% of specimens within five days.
Diagnostic accuracy
Fifty-nine (38%) patients referred for Xpert received empiric TB treatment, including 5/79 (6.3%) rated as low probability for TB, 23/44 (52%) rated as moderate probability, and 31/33 (94%) rated as high probability. A decision to treat empirically for TB had high sensitivity (12/13, 92%, 95%CI 64-100) and high negative-predictive value (NPV, 96/97, 99%, 95%CI 94-100) for culture-positive TB. However, the specificity of empiric treatment decisions was poor (96/143, 67%, 95%CI 59-75), and only 12 of 59 patients starting empiric treatment actually had TB (positive-predictive value, PPV, 20%, 95%CI 11-33) ( Figure 2 ).
Xpert had identical sensitivity to clinician-guided treatment decisions (sensitivity difference 0%, 95%CI -29 to +29, p=1.0), detecting all eleven patients with positive AFB-smear microscopy results (sensitivity 100%, 95%CI 72-100), and one of two patients with negative microscopy results (sensitivity 50%, 95%CI 1-100) (Online Supplement, Figure S1 ). Xpert also had a high NPV (140/141, 99%, 95%CI 96-100), which did not vary significantly by smear status, indication for Xpert testing, or level of clinicianestimated probability of TB (Online supplement, Figures S1-S3).
The specificity of Xpert (140/143, 98%, 95%CI 94-100) was considerably higher than that of clinician-guided treatment decisions (difference +31%, 95%CI +22 to +39, p<0.0001), and correctly excluded TB in three AFB smear-positive patients with Mycobacterium avium complex (MAC) infection.
Twelve of 15 patients with positive Xpert results also had positive cultures (PPV 80%, 95%CI 52-96).
Among 15 patients testing Xpert-positive, three had positive tests for rifampin resistance; all were confirmed by phenotypic drug-susceptibility testing.
Discordant Xpert and culture results
One patient had a negative Xpert result but a positive sputum culture: an HIV-infected patient with negative AFB-smear microscopy results, low CD4 count, and minimally abnormal chest radiography, in whom the managing clinician estimated a high clinical probability of active TB and initiated empiric 
Contact investigation
The standard indications for contact investigation, having positive AFB smear-microscopy results or chest radiographic findings consistent with active TB and receiving empiric TB therapy, were present in 81/156 (52%) of patients. The sensitivity of these criteria for culture-positive TB was 92% (95%CI 64-100); specificity was 52% (95%CI 43-60) (Figure 2 ). Although the NPV of standard criteria for contact investigation was high (99%, 95%CI 93-100), only 12/81 (PPV 15%, 95%CI 8-24) meeting these criteria actually had TB. Xpert identified one patient with AFB-smear-negative, culture-positive TB with a normal chest radiograph that programmatic criteria did not select for contact investigation, but missed another patient with AFB-smear-negative, culture-positive TB and an abnormal radiograph that programmatic criteria identified, thereby yielding no net change in the number of contact investigations (sensitivity difference 0%, 95%CI -29 to +29, p=1.0). The specificity of Xpert, however, was 46% higher (95%CI 37-55, p<0.0001) than standard criteria for contact investigation. Therefore, Xpert would have hypothetically eliminated 66 unnecessary contact investigations, and reduced the overall number of contacts of non-TB patients screened as case contacts from 99 to 9 ( Table 2) .
Housing
Among the 20 homeless patients, eleven had indications for subsidized housing, including ten receiving empiric TB treatment for whom housing was part of a broader package of social support, and one individual in whom the clinical probability for TB was moderate and housing was indicated to address infection control concerns. Both programmatic criteria for providing housing and Xpert correctly identified the single homeless patient with culture-positive TB (sensitivity 100%, 95%CI 3-100), and had perfect NPV for excluding TB (100% for programmatic criteria, 95%CI 66-100, and 100% for Xpert, 95%CI 82-100) (Figure 2 ). However, specificity of the standard algorithm was poor (9/19, 47%, 95%CI 24-71), and only one of eleven patients with a programmatic indication for housing actually had TB (PPV 9%, 95%CI 0-41). The specificity of Xpert (19/19, 100%, 95%CI 82-100) was much higher (specificity difference +53%, 95%CI +25 to +80) and PPV was 100% (95%CI 3-100). Using Xpert instead of standard programmatic criteria would have decreased the median number of nights of unnecessary housing from 47 (IQR 46-49) to 1 (IQR 1-4) , and the total number of nights of unnecessary housing from 495 (95%CI 387-603) to 30 (95%CI 6-54) ( Table 2) .
DISCUSSION
Recent advances in evidence synthesis for policy-making emphasize the need for data on outcomes important to patients and public health programs (24). In this study, we have addressed this important TB research priority (37) by projecting the impact of a novel, automated TB NAAT on key clinical and programmatic management decisions prior to the availability of final mycobacterial culture results in patients undergoing evaluation for active pulmonary TB. In our TB program clinic in San Francisco, we found that over 80% of the treatment, contact investigation, and housing interventions provided during the initial eight-week evaluation period went to individuals who ultimately proved not to have active pulmonary TB by either the culture reference standard or final clinician determination.
Furthermore, we found that replacing standard evaluation algorithms with a single sputum Xpert test could eliminate almost all unnecessary interventions in patients without TB, without adversely impacting the timely and appropriate use of these interventions in patients with TB.
There are several reasons why overuse of empiric treatment and other early TB interventions prior to the availability of mycobacterial culture results is common in San Francisco and in other public health settings (17, 18) . First, although standard algorithms for treating, investigating, and housing outpatients with possible TB are inefficient, they are nonetheless highly effective at detecting and excluding culture-positive TB, as shown by their high sensitivity (≥90%) and negative predictive value (≥99%) in this study. Second, while researchers, professional societies, and TB programs have consistently highlighted the public health consequences of missing TB patients in epidemiologic studies and practice guidelines (7-9, 31, 38, 39), few investigators have examined the impact of an incorrect TB diagnosis on patients (5, 30) . A recent survey found that only three of 96 published systematic reviews and meta-analyses of TB diagnostic strategies had addressed questions related to clinical or public health impact (40) , and similar gaps exist in the primary literature (41) . Because of a lack of high-quality comparative data on the costs of under-management and over-management of TB, clinicians and public health programs consistently underestimate the adverse consequences of false-positive results -and the resulting unnecessary treatments, contact investigations, and housing orders -thereby obscuring the negative effects that standard strategies have on patients and TB programs (42) . As we have shown, incorrect initial management decisions adversely impact a large proportion of individuals being evaluated and have sustained adverse consequences for patients and families, including anxiety, stigma, drug toxicities and interactions, and missed primary diagnoses. In addition, misclassification errors take a heavy toll on public health departments, leading to poor allocation of medications, laboratory tests, and staff time, and undermining patient confidence in the competence of TB programs, in an era when public health funding is increasingly tight (43) (44) (45) .
We have shown that introducing Xpert could reduce the need to rely on non-specific clinical and programmatic algorithms, and accelerate and improve most initial decisions so that they better serve patients and public health programs. In our study, both Xpert and the standard algorithm correctly excluded culture-positive TB in 99% of individuals, but because of its superior specificity, Xpert would have averted many unnecessary courses of empiric four-drug treatment for active TB, many unnecessary contact investigations, and a few nights of housing. If this strategy were implemented, a few patients with culture-positive or culture-negative TB might be initially missed and have early interventions incorrectly withheld, but such misclassifications also happen with current clinical algorithms. Moreover, we would hypothesize that because Xpert-negative patients have pauci-bacillary disease (46) , most are unlikely to experience adverse outcomes or transmit TB in the short two-to-four weeks required for liquid cultures to turn positive (47) . For the minority of patients who have features of extra-pulmonary TB or risk factors for rapid disease progression; who are residing or receiving care amidst a vulnerable population; or for whom the quality of sputum is uncertain, clinicians may choose to conservatively provide initial empiric treatment and/or housing regardless of the Xpert result, while contact investigation may await the final clinical determination. In addition, for patients who later prove to be sputum culture-negative but for whom concerning clinical features of TB persist, clinicians should consider empiric treatment of presumptive culture-negative TB at that time.
Our findings complement previous studies of the impact of TB NAATs by providing hypothetical patient-and clinic-level outcome data on the new Xpert assay in a highly relevant population. A study from a North Carolina public health program projected that an idealized NAAT with characteristics similar to Xpert could reduce treatment costs by 54%, respiratory isolation costs by 75%, and contact investigation costs by 13% (45) . Operational data from Georgia, Hawaii, Maryland, and Massachusetts using the older Mycobacterium tuberculosis Direct (MTD, GenProbe, San Diego, CA) NAAT to evaluate patients for TB showed reductions in unnecessary empiric treatment, respiratory isolation, and contact investigation, but greater overall costs (19) . Finally, a mathematical model comparing Xpert, MTD, and standard microbiologic testing for patients undergoing TB evaluation in the U.S. found Xpert to be costsaving relative to the other approaches. Moreover, universal Xpert testing modestly improved quality of life at a modest incremental cost relative to testing only patients with positive sputum smears (47) .
Future studies should also account for the economic and social costs borne by individuals, in order to better understand the impact of TB diagnostic strategies on patient-important outcomes.
Our study has limitations. First, patients were not selected consecutively but based on the presence of diagnostic uncertainty. Although this kind of sampling may upwardly bias measures of diagnostic accuracy, our pragmatic, "intention-to-test" enrollment strategy is consistent with CDC guidelines to refer only those for whom a result would alter clinical or public health decisions (9, 48).
Second, because of the small number of TB cases, our sensitivity measures for Xpert had limited precision, although the point estimates were identical to those reported in multiple studies from other low-burden settings (49) , and the negative predictive values were high and precise. Third, we used a concentrated pellet rather than a clinical specimen for the Xpert assays, which has been associated with higher sensitivity in some studies and lower sensitivity in others, but to have no effect on specificity (49) .
Nevertheless, in our low-burden population, the reported sensitivity differences between direct and pelleted specimens would not meaningfully alter Xpert's negative predictive value. Fourth, we did not collect data on the effects of sputum volume, type of collection, or quality on Xpert accuracy. However, limited published data suggest that reductions in sensitivity observed with low-volume or induced sputa have only modest effects on negative predictive value, especially in low-burden settings, and that patients missed by Xpert have paucibacillary disease often detected by sputum culture within only a few weeks (46, 50) .
Finally, our estimates of the clinical and public health impact of Xpert are hypothetical.
However, a clinical trial comparing clinician-and Xpert-guided decisions in low-burden settings is unlikely to be performed anytime soon, and would arguably be unnecessary and unethical given the overwhelming potential benefit in reducing unnecessary management (51) . Instead, implementation studies are needed to inform the safety and acceptability of Xpert-guided management decisions in various low-burden settings, with close monitoring of populations in whom negative predictive value is uncertain and of populations who are at high risk of transmitting TB or of progressing rapidly to more severe disease. We did not directly examine the economic costs of the proposed strategy, although others project substantial savings (45, 52) . Future analyses using this detailed data may further define the individual and public health costs and benefits, and inform use of Xpert within new TB evaluation algorithms where resources are constrained.
In summary, routine use of Xpert could potentially have substantial clinical and public health impact by reducing empiric treatment, contact investigation, and housing for many patients who do not have TB in low-burden settings. Our data provide a strong argument for using Xpert and other similar tests in the majority of presumed pulmonary TB patients in programmatic settings, and for practicebased research using closely monitored and well-controlled research designs to evaluate their safety and benefits in patients with uncertain sputum quality, or with risk factors for rapid progression or transmission to vulnerable populations. Xpert is already revolutionizing TB diagnosis in high-burden countries, and could improve patient well-being and resource allocation in low-burden countries, enabling programs to focus on identifying and treating patients who actually have TB. (41) 24 (41) ≥1 risk factor for TB-drug-related hepatotoxicity §
17 (18) 16 (27) Risk factors for rapid TB progression 8 (8) 9 (15) HIV-seropositive 6 (6) 7 (12) Immunosuppression, not due to HIV 1 (1) 1 (2) AFB-smear-positive 6 (6) 16 (27) Culture-confirmed TB 0 (0) 11 ( Legend: * Unless otherwise specified. † 9/59 (15%) empirically treated patients were homeless but analyzed with the empirically treated group rather than with the congregate settings group. ‡ 6 missing observations, 5 from the congregate settings group and one from the empirically treated group. ¶ Including antiretroviral therapy, oral contraceptives, immunosuppressive therapy, and methadone.
§ Including ethanol use, chronic liver disease, and viral hepatitis. 
Mtb culture-negative associates for active and latent TB infection at home or in the community (2) . Eight weeks after the initial clinic evaluation, clinicians review all clinical, microbiologic, and radiographic data, including any evidence of improvement among those receiving treatment, and assign a final diagnosis.
Inclusion and exclusion criteria
We excluded patients from the San Francisco County Jail as a vulnerable population. 
Statistical analysis
We compared clinical characteristics of those tested and not tested with Xpert within each testing subgroup, using generalized linear models with a log link and robust standard errors.
SUPPLEMENTARY RESULTS
Among the 354 patients with final culture results available whom clinicians chose not to refer for Xpert, only 13 (3.7%) had culture-positive TB. Therefore, although the sensitivity of smear microscopy (6/13, 46%, 95%CI 19-75) was only fair, negative predictive value (340/347, 98%, 95%CI 96-99) was excellent.
In addition, the specificity of smear microscopy (340/341, 99.7%, 95%CI 98-100) was high, as was the positive predictive value (6/7, 86%, 95%CI 42-100), albeit within wide confidence intervals. Figure S3 . Comparison of diagnostic accuracy and impact of clinician-versus Xpert-guided decisions among patients undergoing evaluation for active pulmonary TB by initial clinicianestimated probability of TB: (A) low probability (n=79), (B) low probability (n=44), (C) high probability (n=33). 
